You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRosuvastatin
Accession NumberDB01098  (APRD00546)
TypeSmall Molecule
GroupsApproved
DescriptionRosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Rosuvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.
Structure
Thumb
Synonyms
(3R,5S,6e)-7-(4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid
(3R,5S,6e)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid
External Identifiers
  • ZD-4522
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-rosuvastatinTablet40 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-rosuvastatinTablet5 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-rosuvastatinTablet10 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-rosuvastatinTablet20 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Act RosuvastatinTablet5 mgOralActavis Pharma Company2012-03-16Not applicableCanada
Act RosuvastatinTablet10 mgOralActavis Pharma Company2012-03-16Not applicableCanada
Act RosuvastatinTablet20 mgOralActavis Pharma Company2012-03-16Not applicableCanada
Act RosuvastatinTablet40 mgOralActavis Pharma Company2012-03-16Not applicableCanada
Auro-rosuvastatinTablet40 mgOralAuro Pharma Inc2015-11-30Not applicableCanada
Auro-rosuvastatinTablet5 mgOralAuro Pharma Inc2015-11-30Not applicableCanada
Auro-rosuvastatinTablet10 mgOralAuro Pharma Inc2015-11-30Not applicableCanada
Auro-rosuvastatinTablet20 mgOralAuro Pharma Inc2015-11-30Not applicableCanada
Bio-rosuvastatinTablet40 mgOralBiomed Pharma2016-06-29Not applicableCanada
Bio-rosuvastatinTablet5 mgOralBiomed Pharma2016-06-29Not applicableCanada
Bio-rosuvastatinTablet10 mgOralBiomed Pharma2016-06-30Not applicableCanada
Bio-rosuvastatinTablet20 mgOralBiomed Pharma2016-06-30Not applicableCanada
CrestorTablet, film coated10 mg/1OralAphena Pharma Solutions Tennessee, Inc.2003-08-18Not applicableUs
CrestorTablet, film coated20 mg/1OralCardinal Health2010-12-01Not applicableUs
CrestorTablet, film coated40 mg/1OralA S Medication Solutions2003-08-18Not applicableUs
CrestorTablet, film coated10 mg/1OralAstra Zeneca Lp2003-08-18Not applicableUs
CrestorTablet, film coated10 mg/1OralRebel Distributors2003-11-25Not applicableUs
CrestorTablet, film coated5 mg/1OralA S Medication Solutions2005-10-26Not applicableUs
CrestorTablet, film coated5 mg/1OralRemedy Repack2013-02-272016-10-13Us
CrestorTablet, film coated10 mg/1OralPd Rx Pharmaceuticals, Inc.2003-08-18Not applicableUs
CrestorTablet, coated40 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2010-09-08Not applicableUs
CrestorTablet, film coated5 mg/1OralPhysicians Total Care, Inc.2005-06-22Not applicableUs
CrestorTablet, film coated5 mg/1OralCarilion Materials Management2003-08-18Not applicableUs
CrestorTablet, film coated40 mg/1OralCardinal Health2010-12-01Not applicableUs
CrestorTablet, film coated40 mg/1OralMesource Pharmaceuticals2003-08-18Not applicableUs
CrestorTablet, film coated20 mg/1OralRebel Distributors2004-06-07Not applicableUs
CrestorTablet, film coated40 mg/1OralPhysicians Total Care, Inc.2004-11-01Not applicableUs
CrestorTablet, film coated20 mg/1OralAstra Zeneca Lp2003-08-18Not applicableUs
CrestorTablet, film coated20 mg/1OralH.J. Harkins Company2011-07-21Not applicableUs
CrestorTablet, film coated10 mg/1Oralbryant ranch prepack2010-12-01Not applicableUs
CrestorTablet, film coated20 mg/1Oralbryant ranch prepack2003-08-18Not applicableUs
CrestorTablet, film coated40 mg/1OralAphena Pharma Solutions Tennessee, Inc.2003-08-18Not applicableUs
CrestorTablet, film coated10 mg/1OralCardinal Health2010-12-01Not applicableUs
CrestorTablet, film coated40 mg/1OralA S Medication Solutions2003-08-18Not applicableUs
CrestorTablet, coated10 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2010-11-09Not applicableUs
CrestorTablet, film coated20 mg/1OralCardinal Health2010-12-01Not applicableUs
CrestorTablet, film coated40 mg/1OralRebel Distributors2004-11-01Not applicableUs
CrestorTablet, film coated10 mg/1OralPhysicians Total Care, Inc.2003-11-25Not applicableUs
CrestorTablet, film coated40 mg/1OralAstra Zeneca Lp2003-08-18Not applicableUs
CrestorTablet, film coated10 mg/1OralA S Medication Solutions2004-09-02Not applicableUs
CrestorTablet, film coated5 mg/1Oralbryant ranch prepack2003-08-18Not applicableUs
CrestorTablet, film coated5 mg/1Oralbryant ranch prepack2003-08-18Not applicableUs
CrestorTablet, film coated20 mg/1OralAphena Pharma Solutions Tennessee, Inc.2003-08-18Not applicableUs
CrestorTablet, film coated10 mg/1OralCardinal Health2010-12-01Not applicableUs
CrestorTablet, film coated5 mg/1OralCardinal Health2010-12-01Not applicableUs
CrestorTablet, film coated20 mg/1OralA S Medication Solutions2003-08-18Not applicableUs
CrestorTablet, film coated20 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-02-27Not applicableUs
CrestorTablet, film coated20 mg/1OralPd Rx Pharmaceuticals, Inc.2003-08-18Not applicableUs
CrestorTablet, film coated5 mg/1OralRebel Distributors2005-06-22Not applicableUs
CrestorTablet, film coated20 mg/1OralPhysicians Total Care, Inc.2004-06-07Not applicableUs
CrestorTablet, film coated5 mg/1OralAstra Zeneca Lp2003-08-18Not applicableUs
CrestorTablet, film coated20 mg/1OralA S Medication Solutions2005-04-14Not applicableUs
CrestorTablet, film coated5 mg/1Oralbryant ranch prepack2010-12-01Not applicableUs
Crestor - 10mgTablet10 mgOralAstra Zeneca2003-02-19Not applicableCanada
Crestor - 20mgTablet20 mgOralAstra Zeneca2003-02-19Not applicableCanada
Crestor - 40mgTablet40 mgOralAstra Zeneca2003-02-19Not applicableCanada
Crestor - 5mgTablet5 mgOralAstra Zeneca2005-03-18Not applicableCanada
Dom-rosuvastatinTablet20 mgOralDominion Pharmacal2013-09-28Not applicableCanada
Dom-rosuvastatinTablet5 mgOralDominion Pharmacal2013-09-28Not applicableCanada
Dom-rosuvastatinTablet40 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-rosuvastatinTablet10 mgOralDominion Pharmacal2013-09-28Not applicableCanada
Ipg-rosuvastatinTablet40 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-rosuvastatinTablet5 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-rosuvastatinTablet10 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-rosuvastatinTablet20 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-rosuvastatinTablet20.0 mgOralJamp Pharma Corporation2012-09-24Not applicableCanada
Jamp-rosuvastatinTablet40.0 mgOralJamp Pharma Corporation2012-09-24Not applicableCanada
Jamp-rosuvastatinTablet5 mgOralJamp Pharma Corporation2012-09-24Not applicableCanada
Jamp-rosuvastatinTablet10.0 mgOralJamp Pharma Corporation2012-09-24Not applicableCanada
Mar-rosuvastatinTablet40 mgOralMarcan Pharmaceuticals Inc2014-06-26Not applicableCanada
Mar-rosuvastatinTablet5 mgOralMarcan Pharmaceuticals Inc2014-06-26Not applicableCanada
Mar-rosuvastatinTablet10 mgOralMarcan Pharmaceuticals Inc2014-06-26Not applicableCanada
Mar-rosuvastatinTablet20 mgOralMarcan Pharmaceuticals Inc2014-06-26Not applicableCanada
Med-rosuvastatinTablet20 mgOralGeneric Medical Partners Inc2013-11-27Not applicableCanada
Med-rosuvastatinTablet40 mgOralGeneric Medical Partners Inc2013-11-27Not applicableCanada
Med-rosuvastatinTablet5 mgOralGeneric Medical Partners Inc2013-11-27Not applicableCanada
Med-rosuvastatinTablet10 mgOralGeneric Medical Partners Inc2013-11-27Not applicableCanada
Mint-rosuvastatinTablet20 mgOralMint Pharmaceuticals Inc2013-07-02Not applicableCanada
Mint-rosuvastatinTablet40 mgOralMint Pharmaceuticals Inc2013-07-02Not applicableCanada
Mint-rosuvastatinTablet5 mgOralMint Pharmaceuticals Inc2013-07-02Not applicableCanada
Mint-rosuvastatinTablet10 mgOralMint Pharmaceuticals Inc2013-07-02Not applicableCanada
Mylan-rosuvastatinTablet20 mgOralMylan Pharmaceuticals2012-03-15Not applicableCanada
Mylan-rosuvastatinTablet40 mgOralMylan Pharmaceuticals2012-04-17Not applicableCanada
Mylan-rosuvastatinTablet5 mgOralMylan Pharmaceuticals2012-03-15Not applicableCanada
Mylan-rosuvastatinTablet10 mgOralMylan Pharmaceuticals2012-03-15Not applicableCanada
Novo-rosuvastatinTablet40 mgOralTevaNot applicableNot applicableCanada
Novo-rosuvastatinTablet5 mgOralTevaNot applicableNot applicableCanada
Novo-rosuvastatinTablet10 mgOralTevaNot applicableNot applicableCanada
Novo-rosuvastatinTablet20 mgOralTevaNot applicableNot applicableCanada
Ntp-rosuvastatinTablet10 mgOralTevaNot applicableNot applicableCanada
Ntp-rosuvastatinTablet20 mgOralTevaNot applicableNot applicableCanada
Ntp-rosuvastatinTablet40 mgOralTevaNot applicableNot applicableCanada
Ntp-rosuvastatinTablet5 mgOralTevaNot applicableNot applicableCanada
PMS-rosuvastatinTablet5 mgOralPharmascience Inc2012-03-15Not applicableCanada
PMS-rosuvastatinTablet10 mgOralPharmascience Inc2012-03-15Not applicableCanada
PMS-rosuvastatinTablet20 mgOralPharmascience Inc2012-03-15Not applicableCanada
PMS-rosuvastatinTablet40 mgOralPharmascience Inc2012-03-15Not applicableCanada
Priva-rosuvastatinTablet5 mgOralPharmapar Inc2016-06-29Not applicableCanada
Priva-rosuvastatinTablet40 mgOralPharmapar IncNot applicableNot applicableCanada
Priva-rosuvastatinTablet10 mgOralPharmapar Inc2016-06-30Not applicableCanada
Priva-rosuvastatinTablet20 mgOralPharmapar Inc2016-06-30Not applicableCanada
Q-rosuvastatinTablet40.0 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-rosuvastatinTablet5 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-rosuvastatinTablet10.0 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-rosuvastatinTablet20.0 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Ran-rosuvastatinTablet20 mgOralRanbaxy Inc.2012-04-02Not applicableCanada
Ran-rosuvastatinTablet40 mgOralRanbaxy Inc.2012-04-02Not applicableCanada
Ran-rosuvastatinTablet5 mgOralRanbaxy Inc.2012-04-02Not applicableCanada
Ran-rosuvastatinTablet10 mgOralRanbaxy Inc.2012-04-02Not applicableCanada
Riva-rosuvastatinTablet40 mgOralLaboratoire Riva Inc2012-06-13Not applicableCanada
Riva-rosuvastatinTablet5 mgOralLaboratoire Riva Inc2012-06-11Not applicableCanada
Riva-rosuvastatinTablet10 mgOralLaboratoire Riva Inc2012-06-11Not applicableCanada
Riva-rosuvastatinTablet20 mgOralLaboratoire Riva Inc2012-06-13Not applicableCanada
RosuvastatinTablet5 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
RosuvastatinTablet5 mgOralSanis Health Inc2013-06-12Not applicableCanada
RosuvastatinTablet5.0 mgOralRanbaxy Inc.Not applicableNot applicableCanada
RosuvastatinTablet40 mgOralPro Doc Limitee2012-07-19Not applicableCanada
RosuvastatinTablet40 mgOralSivem Pharmaceuticals Ulc2012-07-11Not applicableCanada
RosuvastatinTablet10 mgOralSanis Health Inc2013-06-12Not applicableCanada
RosuvastatinTablet5 mgOralPro Doc Limitee2012-07-19Not applicableCanada
RosuvastatinTablet5 mgOralSivem Pharmaceuticals Ulc2012-07-11Not applicableCanada
RosuvastatinTablet10 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
RosuvastatinTablet10.0 mgOralRanbaxy Inc.Not applicableNot applicableCanada
RosuvastatinTablet20 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
RosuvastatinTablet20 mgOralSanis Health Inc2013-06-12Not applicableCanada
RosuvastatinTablet10 mgOralPro Doc Limitee2012-07-19Not applicableCanada
RosuvastatinTablet10 mgOralSivem Pharmaceuticals Ulc2012-07-11Not applicableCanada
RosuvastatinTablet20.0 mgOralRanbaxy Inc.Not applicableNot applicableCanada
RosuvastatinTablet20 mgOralPro Doc Limitee2012-07-19Not applicableCanada
RosuvastatinTablet20 mgOralSivem Pharmaceuticals Ulc2012-07-11Not applicableCanada
RosuvastatinTablet40 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
RosuvastatinTablet40 mgOralSanis Health Inc2013-06-12Not applicableCanada
RosuvastatinTablet40.0 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Rosuvastatin-10Tablet10 mgOralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Rosuvastatin-20Tablet20 mgOralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Rosuvastatin-40Tablet40 mgOralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Rosuvastatin-5Tablet5 mgOralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Sandoz RosuvastatinTablet40 mgOralSandoz Canada Incorporated2012-03-15Not applicableCanada
Sandoz RosuvastatinTablet5 mgOralSandoz Canada Incorporated2012-03-15Not applicableCanada
Sandoz RosuvastatinTablet10 mgOralSandoz Canada Incorporated2012-03-15Not applicableCanada
Sandoz RosuvastatinTablet20 mgOralSandoz Canada Incorporated2012-03-15Not applicableCanada
Teva-rosuvastatinTablet40 mgOralTeva2012-03-15Not applicableCanada
Teva-rosuvastatinTablet5 mgOralTeva2012-03-15Not applicableCanada
Teva-rosuvastatinTablet10 mgOralTeva2012-03-15Not applicableCanada
Teva-rosuvastatinTablet20 mgOralTeva2012-03-15Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-rosuvastatinTablet5 mgOralApotex Corporation2012-04-02Not applicableCanada
Apo-rosuvastatinTablet10 mgOralApotex Corporation2012-04-02Not applicableCanada
Apo-rosuvastatinTablet20 mgOralApotex Corporation2012-04-02Not applicableCanada
Apo-rosuvastatinTablet40 mgOralApotex Corporation2012-04-02Not applicableCanada
RosuvastatinTablet, film coated10 mg/1OralA S Medication Solutions2016-10-29Not applicableUs
RosuvastatinTablet, film coated10 mg/1OralGolden State Medical Supply2016-09-122017-02-07Us
RosuvastatinTablet, film coated10 mg/1OralApotex Corporation2016-07-20Not applicableUs
RosuvastatinTablet, film coated10 mg/1OralCamber Pharmaceuticals2016-10-29Not applicableUs
RosuvastatinTablet, film coated20 mg/1OralA S Medication Solutions2016-10-29Not applicableUs
RosuvastatinTablet, film coated20 mg/1OralGolden State Medical Supply2016-09-122017-02-07Us
RosuvastatinTablet, film coated20 mg/1OralApotex Corporation2016-07-20Not applicableUs
RosuvastatinTablet, film coated20 mg/1OralCamber Pharmaceuticals2016-10-29Not applicableUs
RosuvastatinTablet, film coated40 mg/1OralA S Medication Solutions2016-10-29Not applicableUs
RosuvastatinTablet, film coated40 mg/1OralGolden State Medical Supply2016-09-122017-02-07Us
RosuvastatinTablet, film coated40 mg/1OralApotex Corporation2016-07-20Not applicableUs
RosuvastatinTablet, film coated40 mg/1OralCamber Pharmaceuticals2016-10-29Not applicableUs
RosuvastatinTablet, film coated5 mg/1OralA S Medication Solutions2016-10-29Not applicableUs
RosuvastatinTablet, film coated5 mg/1OralApotex Corporation2016-07-20Not applicableUs
RosuvastatinTablet, film coated5 mg/1OralCamber Pharmaceuticals2016-10-29Not applicableUs
RosuvastatinTablet, film coated5 mg/1OralGolden State Medical Supply2016-09-122017-02-07Us
Rosuvastatin CalciumTablet, film coated10 mg/1OralCitron Pharma LLC2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated20 mg/1OralAurobindo Pharma2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated5 mg/1OralAccord Healthcare Limited2016-10-31Not applicableUs
Rosuvastatin CalciumTablet, film coated40 mg/1OralBiocon Pharma Inc,2016-10-31Not applicableUs
Rosuvastatin CalciumTablet, film coated40 mg/1OralTeva2016-08-18Not applicableUs
Rosuvastatin CalciumTablet20 mg/1OralAv Kare, Inc.2016-07-22Not applicableUs
Rosuvastatin CalciumTablet, film coated20 mg/1OralSun Pharma Global FZE2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated10 mg/1OralAmerincan Health Packaging2016-09-15Not applicableUs
Rosuvastatin CalciumTablet, coated5 mg/1OralTorrent Pharmaceuticals Limited2016-10-31Not applicableUs
Rosuvastatin CalciumTablet20 mg/1OralRemedy Repack2017-01-20Not applicableUs
Rosuvastatin CalciumTablet, film coated40 mg/1OralSandoz2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated20 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated5 mg/1OralJubilant Cadista Pharmaceuticals Inc.2016-10-31Not applicableUs
Rosuvastatin CalciumTablet10 mg/1OralMajor2016-05-02Not applicableUs
Rosuvastatin CalciumTablet, film coated5 mg/1OralUnit Dose Services2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated40 mg/1OralMylan Pharmaceuticals2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated20 mg/1OralMylan Institutional2016-08-16Not applicableUs
Rosuvastatin CalciumTablet20 mg/1OralPar Pharmaceutical2016-07-19Not applicableUs
Rosuvastatin CalciumTablet40 mg/1OralRemedy Repack2016-08-19Not applicableUs
Rosuvastatin CalciumTablet, film coated5 mg/1OralBiocon Pharma Inc,2016-10-31Not applicableUs
Rosuvastatin CalciumTablet, film coated10 mg/1OralA S Medication Solutions2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated5 mg/1OralTeva2016-08-18Not applicableUs
Rosuvastatin CalciumTablet40 mg/1OralActavis Pharma Company2016-05-02Not applicableUs
Rosuvastatin CalciumTablet40 mg/1OralAv Kare, Inc.2016-07-22Not applicableUs
Rosuvastatin CalciumTablet, film coated20 mg/1OralCitron Pharma LLC2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated40 mg/1OralAurobindo Pharma2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated10 mg/1OralAccord Healthcare Limited2016-10-31Not applicableUs
Rosuvastatin CalciumTablet, film coated20 mg/1OralPreferred Pharmaceuticals Incl2016-11-08Not applicableUs
Rosuvastatin CalciumTablet, film coated5 mg/1OralMylan Pharmaceuticals2016-07-19Not applicableUs
Rosuvastatin CalciumTablet5 mg/1OralActavis Pharma Company2016-05-02Not applicableUs
Rosuvastatin CalciumTablet, film coated40 mg/1OralSun Pharma Global FZE2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated20 mg/1OralAmerincan Health Packaging2016-09-15Not applicableUs
Rosuvastatin CalciumTablet, coated10 mg/1OralTorrent Pharmaceuticals Limited2016-10-31Not applicableUs
Rosuvastatin CalciumTablet, film coated5 mg/1OralA S Medication Solutions2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated40 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated10 mg/1OralJubilant Cadista Pharmaceuticals Inc.2016-10-31Not applicableUs
Rosuvastatin CalciumTablet20 mg/1OralMajor2016-05-02Not applicableUs
Rosuvastatin CalciumTablet, film coated10 mg/1OralUnit Dose Services2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated5 mg/1OralSandoz2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated40 mg/1OralMylan Institutional2016-08-16Not applicableUs
Rosuvastatin CalciumTablet40 mg/1OralPar Pharmaceutical2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated5 mg/1OralAurobindo Pharma2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated10 mg/1OralBiocon Pharma Inc,2016-10-31Not applicableUs
Rosuvastatin CalciumTablet, film coated10 mg/1OralA S Medication Solutions2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated10 mg/1OralTeva2016-08-18Not applicableUs
Rosuvastatin CalciumTablet5 mg/1OralAv Kare, Inc.2016-07-22Not applicableUs
Rosuvastatin CalciumTablet, film coated10 mg/1OralMylan Pharmaceuticals2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated5 mg/1OralMylan Institutional2016-08-15Not applicableUs
Rosuvastatin CalciumTablet, film coated40 mg/1OralCitron Pharma LLC2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated5 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated20 mg/1OralAccord Healthcare Limited2016-10-31Not applicableUs
Rosuvastatin CalciumTablet, film coated40 mg/1OralPreferreed Pharmaceuticals Inc.2016-11-17Not applicableUs
Rosuvastatin CalciumTablet, coated20 mg/1OralTorrent Pharmaceuticals Limited2016-10-31Not applicableUs
Rosuvastatin CalciumTablet, film coated40 mg/1OralA S Medication Solutions2016-07-19Not applicableUs
Rosuvastatin CalciumTablet10 mg/1OralActavis Pharma Company2016-05-02Not applicableUs
Rosuvastatin CalciumTablet5 mg/1OralPar Pharmaceutical2016-07-19Not applicableUs
Rosuvastatin CalciumTablet10 mg/1OralRemedy Repack2016-08-19Not applicableUs
Rosuvastatin CalciumTablet, film coated10 mg/1OralPreferreed Pharmaceuticals Inc.2016-10-10Not applicableUs
Rosuvastatin CalciumTablet, film coated20 mg/1OralJubilant Cadista Pharmaceuticals Inc.2016-10-31Not applicableUs
Rosuvastatin CalciumTablet40 mg/1OralMajor2016-05-02Not applicableUs
Rosuvastatin CalciumTablet, film coated20 mg/1OralUnit Dose Services2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated10 mg/1OralSandoz2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated5 mg/1OralSun Pharma Global FZE2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated5 mg/1OralCitron Pharma LLC2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated10 mg/1OralAurobindo Pharma2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated20 mg/1OralBiocon Pharma Inc,2016-10-31Not applicableUs
Rosuvastatin CalciumTablet, film coated20 mg/1OralTeva2016-08-18Not applicableUs
Rosuvastatin CalciumTablet10 mg/1OralAv Kare, Inc.2016-07-22Not applicableUs
Rosuvastatin CalciumTablet, film coated40 mg/1OralAccord Healthcare Limited2016-10-31Not applicableUs
Rosuvastatin CalciumTablet5 mg/1OralMajor2016-05-02Not applicableUs
Rosuvastatin CalciumTablet40 mg/1OralA S Medication Solutions2016-05-02Not applicableUs
Rosuvastatin CalciumTablet, film coated20 mg/1OralMylan Pharmaceuticals2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated10 mg/1OralMylan Institutional2016-08-15Not applicableUs
Rosuvastatin CalciumTablet, film coated10 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2016-07-19Not applicableUs
Rosuvastatin CalciumTablet20 mg/1OralRemedy Repack2016-08-19Not applicableUs
Rosuvastatin CalciumTablet, coated40 mg/1OralTorrent Pharmaceuticals Limited2016-10-31Not applicableUs
Rosuvastatin CalciumTablet, film coated20 mg/1OralA S Medication Solutions2016-07-19Not applicableUs
Rosuvastatin CalciumTablet20 mg/1OralActavis Pharma Company2016-05-02Not applicableUs
Rosuvastatin CalciumTablet10 mg/1OralPar Pharmaceutical2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated5 mg/1OralAmerincan Health Packaging2016-09-15Not applicableUs
Rosuvastatin CalciumTablet, film coated40 mg/1OralJubilant Cadista Pharmaceuticals Inc.2016-10-31Not applicableUs
Rosuvastatin CalciumTablet, film coated20 mg/1OralRemedy Repack2016-11-16Not applicableUs
Rosuvastatin CalciumTablet, film coated20 mg/1OralSandoz2016-07-19Not applicableUs
Rosuvastatin CalciumTablet, film coated10 mg/1OralSun Pharma Global FZE2016-07-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AstendeLazar (Argentina)
CirantanAstraZeneca (Netherlands)
CresadexDrugtech (Chile)
Provisacor AstraZeneca (Italy, Netherlands)
RazelGlenmark (India)
RosedexRoux-Ocefa (Argentina)
RosimolSandoz (Argentina)
RosumedLabomed (Chile)
RosustatinMontpellier (Argentina)
RosuvasRanbaxy (India)
RosuvastBago (Argentina)
RosvelLaboratorios Chile (Chile)
RovartalRoemmers (Argentina)
SimestatSimesa (Italy)
SinlipGador (Argentina)
VisacorAstraZeneca (Portugal)
VivacorAstraZeneca (Brazil)
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Rosuvastatin calcium
147098-20-2
Thumb
  • InChI Key: LALFOYNTGMUKGG-BGRFNVSISA-L
  • Monoisotopic Mass: 1000.283510167
  • Average Mass: 1001.137
DBSALT000154
Rosuvastatin zinc
953412-08-3
Thumb
  • InChI Key: KUQHZGJLQWUFPU-BGRFNVSISA-L
  • Monoisotopic Mass: 1024.250062
  • Average Mass: 1026.44
DBSALT001337
Categories
UNII413KH5ZJ73
CAS number287714-41-4
WeightAverage: 481.538
Monoisotopic: 481.168284538
Chemical FormulaC22H28FN3O6S
InChI KeyBPRHUIZQVSMCRT-VEUZHWNKSA-N
InChI
InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1
IUPAC Name
(3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid
SMILES
CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O
Pharmacology
IndicationUsed as an adjunct to dietary therapy to treat primary hyperlipidemia (heterozygous familial and nonfamilial), mixed dyslipidemia and hypertriglyceridemia. Also indicated for homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering therapies or when other such therapies are not available. Furthermore, it is used to slow the progression of atherosclerosis and for primary prevention of cardiovascular disease.
Structured Indications
PharmacodynamicsRosuvastatin is a synthetic, enantiomerically pure antilipemic agent. It is used to lower total cholesterol, low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), non-high density lipoprotein-cholesterol (non-HDL-C), and trigleride (TG) plasma concentrations while increasing HDL-C concentrations. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease and high ratios are associated with higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, rosuvastatin reduces the risk of cardiovascular morbidity and mortality.
Mechanism of actionRosuvastatin is a competitive inhibitor of HMG-CoA reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis. Rosuvastatin acts primarily in the liver. Decreased hepatic cholesterol concentrations stimulate the upregulation of hepatic low density lipoprotein (LDL) receptors which increases hepatic uptake of LDL. Rosuvastatin also inhibits hepatic synthesis of very low density lipoprotein (VLDL). The overall effect is a decrease in plasma LDL and VLDL. In vitro and in vivo animal studies also demonstrate that rosuvastatin exerts vasculoprotective effects independent of its lipid-lowering properties. Rosuvastatin exerts an anti-inflammatory effect on rat mesenteric microvascular endothelium by attenuating leukocyte rolling, adherence and transmigration (PMID: 11375257). The drug also modulates nitric oxide synthase (NOS) expression and reduces ischemic-reperfusion injuries in rat hearts (PMID: 15914111). Rosuvastatin increases the bioavailability of nitric oxide (PMID: 11375257, 12031849, 15914111) by upregulating NOS (PMID: 12354446) and by increasing the stability of NOS through post-transcriptional polyadenylation (PMID: 17916773). It is unclear as to how rosuvastatin brings about these effects though they may be due to decreased concentrations of mevalonic acid.
TargetKindPharmacological actionActionsOrganismUniProt ID
3-hydroxy-3-methylglutaryl-coenzyme A reductaseProteinyes
inhibitor
HumanP04035 details
Related Articles
AbsorptionBioavailability is approximately 20%. Peak plasma concentrations were reached 3 to 5 hours following oral dosing. Both Cmax and AUC increased in approximate proportion to CRESTOR dose. Food has no effect on the AUC of rosuvastatin.
Volume of distribution
  • 134 L [steady-state]
Protein binding88% bound to plasma proteins (mostly albumin). Binding is reversible and independent of plasma concentrations.
Metabolism

Not extensively metabolized. Only ~10% is excreted as metabolite. Cytochrome P450 (CYP) 2C9 is primarily responsible for the formation of rosuvastatin's major metabolite, N-desmethylrosuvastatin. N-desmethylrosuvastatin has approximately 50% of the pharmacological activity of its parent compound in vitro. Rosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to a clinically significant extent. Rosuvastatin accounts for greater than 90% of the pharmacologic action. Inhibitors of CYP2C9 increase the AUC by less than 2-fold. This interaction does not appear to be clinically significant.

SubstrateEnzymesProduct
Rosuvastatin
Rosuvastatin 5 S-lactoneDetails
Rosuvastatin
N-DesmethylrosuvastatinDetails
Route of eliminationRosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite. Following oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%). After an intravenous dose, approximately 28% of total body clearance was via the renal route, and 72% by the hepatic route.
Half life19 hours
ClearanceNot Available
ToxicityGenerally well-tolerated. Side effects may include myalgia, constipation, asthenia, abdominal pain, and nausea. Other possible side effects include myotoxicity (myopathy, myositis, rhabdomyolysis) and hepatotoxicity. To avoid toxicity in Asian patients, lower doses should be considered. Pharmacokinetic studies show an approximately two-fold increase in peak plasma concentration and AUC in Asian patients (Philippino, Chinese, Japanese, Korean, Vietnamese, or Asian-Indian descent) compared to Caucasians patients.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Rosuvastatin Action PathwayDrug actionSMP00092
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Kinesin-like protein KIF6
Gene symbol: KIF6
UniProt: Q6ZMV9
rs20455 ---(C;C) or (C;T)C AlleleImproved response to statin drugs18222353
3-hydroxy-3-methylglutaryl-coenzyme A reductase
Gene symbol: HMGCR
UniProt: P04035
rs17244841 ---(A;T)T AlleleReduced response to statin drugs15199031
ATP-binding cassette sub-family G member 2
Gene symbol: ABCG2
UniProt: Q9UNQ0
rs2231142 ---(A;A) or (A;C)G > TGreater response to drug therapy20130569
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Rosuvastatin can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Rosuvastatin can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Rosuvastatin can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
AbirateroneThe metabolism of Rosuvastatin can be decreased when combined with Abiraterone.Approved
AcenocoumarolRosuvastatin may increase the anticoagulant activities of Acenocoumarol.Approved
AcipimoxAcipimox may increase the myopathic rhabdomyolysis activities of Rosuvastatin.Approved
AlogliptinThe serum concentration of Rosuvastatin can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Rosuvastatin can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
Aluminum hydroxideThe serum concentration of Rosuvastatin can be decreased when it is combined with Aluminum hydroxide.Approved
Aluminum phosphateThe serum concentration of Rosuvastatin can be decreased when it is combined with Aluminum phosphate.Approved
AmiodaroneThe metabolism of Rosuvastatin can be decreased when combined with Amiodarone.Approved, Investigational
AmprenavirThe serum concentration of Rosuvastatin can be increased when it is combined with Amprenavir.Approved
Antithrombin III humanThe serum concentration of Rosuvastatin can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Rosuvastatin can be increased when it is combined with Apixaban.Approved
AprepitantThe serum concentration of Rosuvastatin can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Rosuvastatin can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArgatrobanThe serum concentration of Rosuvastatin can be increased when it is combined with Argatroban.Approved, Investigational
ArmodafinilThe metabolism of Rosuvastatin can be decreased when combined with Armodafinil.Approved, Investigational
AsunaprevirThe serum concentration of Rosuvastatin can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Rosuvastatin can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Rosuvastatin can be decreased when combined with Atomoxetine.Approved
BatimastatThe serum concentration of Rosuvastatin can be increased when it is combined with Batimastat.Experimental
BenazeprilThe serum concentration of Rosuvastatin can be increased when it is combined with Benazepril.Approved, Investigational
BenzamidineThe serum concentration of Rosuvastatin can be increased when it is combined with Benzamidine.Experimental
BexaroteneThe serum concentration of Rosuvastatin can be decreased when it is combined with Bexarotene.Approved, Investigational
BezafibrateBezafibrate may increase the myopathic rhabdomyolysis activities of Rosuvastatin.Approved
Bi201335The serum concentration of Rosuvastatin can be increased when it is combined with Bi201335.Investigational
Bismuth SubcitrateThe serum concentration of Rosuvastatin can be decreased when it is combined with Bismuth Subcitrate.Approved
BivalirudinThe serum concentration of Rosuvastatin can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Rosuvastatin can be increased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Rosuvastatin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe metabolism of Rosuvastatin can be increased when combined with Bosentan.Approved, Investigational
Calcium carbonateThe serum concentration of Rosuvastatin can be decreased when it is combined with Calcium carbonate.Approved
CandoxatrilThe serum concentration of Rosuvastatin can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Rosuvastatin can be increased when it is combined with Candoxatrilat.Experimental
CapecitabineThe metabolism of Rosuvastatin can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Rosuvastatin can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Rosuvastatin can be increased when combined with Carbamazepine.Approved, Investigational
CeritinibThe serum concentration of Rosuvastatin can be increased when it is combined with Ceritinib.Approved
ChloramphenicolThe metabolism of Rosuvastatin can be decreased when combined with Chloramphenicol.Approved, Vet Approved
CholecalciferolThe metabolism of Rosuvastatin can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
ChymostatinThe serum concentration of Rosuvastatin can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Rosuvastatin can be increased when it is combined with Cilazapril.Approved
CimetidineThe metabolism of Rosuvastatin can be decreased when combined with Cimetidine.Approved
CiprofibrateThe risk or severity of adverse effects can be increased when Ciprofibrate is combined with Rosuvastatin.Approved
CitalopramThe metabolism of Rosuvastatin can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Rosuvastatin can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Rosuvastatin can be decreased when combined with Clemastine.Approved
ClopidogrelThe serum concentration of Rosuvastatin can be increased when it is combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Rosuvastatin can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Rosuvastatin can be decreased when combined with Cobicistat.Approved
ColchicineColchicine may increase the myopathic rhabdomyolysis activities of Rosuvastatin.Approved
ConivaptanThe serum concentration of Rosuvastatin can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Rosuvastatin can be decreased when combined with Crizotinib.Approved
CyclosporineThe serum concentration of Rosuvastatin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Rosuvastatin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Rosuvastatin can be increased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Rosuvastatin can be increased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Rosuvastatin can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Rosuvastatin can be increased when it is combined with Daclatasvir.Approved
DanazolThe serum concentration of Rosuvastatin can be increased when it is combined with Danazol.Approved
DaptomycinThe risk or severity of adverse effects can be increased when Rosuvastatin is combined with Daptomycin.Approved, Investigational
DarunavirThe serum concentration of Rosuvastatin can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Rosuvastatin can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Rosuvastatin can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Rosuvastatin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Rosuvastatin can be decreased when combined with Delavirdine.Approved
DexamethasoneThe serum concentration of Rosuvastatin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Rosuvastatin.Approved
DicoumarolRosuvastatin may increase the anticoagulant activities of Dicoumarol.Approved
DihydroergotamineThe metabolism of Rosuvastatin can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Rosuvastatin can be decreased when combined with Diltiazem.Approved
DoxycyclineThe metabolism of Rosuvastatin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Rosuvastatin can be increased when it is combined with Dronedarone.Approved
EcabetThe serum concentration of Rosuvastatin can be increased when it is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Rosuvastatin can be increased when it is combined with Edoxaban.Approved
EfavirenzThe serum concentration of Rosuvastatin can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Rosuvastatin can be increased when it is combined with Elafin.Investigational
EltrombopagThe serum concentration of Rosuvastatin can be increased when it is combined with Eltrombopag.Approved
EluxadolineThe serum concentration of Rosuvastatin can be increased when it is combined with Eluxadoline.Approved
EnalaprilThe serum concentration of Rosuvastatin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Rosuvastatin can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Rosuvastatin can be increased when it is combined with Enalkiren.Experimental
EnzalutamideThe serum concentration of Rosuvastatin can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Rosuvastatin can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Rosuvastatin can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Rosuvastatin can be decreased when combined with Esomeprazole.Approved, Investigational
Ethyl biscoumacetateRosuvastatin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtravirineThe serum concentration of Rosuvastatin can be decreased when it is combined with Etravirine.Approved
FenofibrateThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Rosuvastatin.Approved
FloxuridineThe metabolism of Rosuvastatin can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Rosuvastatin can be decreased when combined with Fluconazole.Approved
FluindioneRosuvastatin may increase the anticoagulant activities of Fluindione.Investigational
FluorouracilThe metabolism of Rosuvastatin can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Rosuvastatin can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluvastatinThe metabolism of Rosuvastatin can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Rosuvastatin can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Rosuvastatin can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Rosuvastatin can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Rosuvastatin can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Rosuvastatin can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Rosuvastatin can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Rosuvastatin can be increased when it is combined with Gabexate.Approved, Investigational
GeldanamycinThe serum concentration of Rosuvastatin can be increased when it is combined with Geldanamycin.Experimental
GemfibrozilGemfibrozil may increase the myopathic rhabdomyolysis activities of Rosuvastatin.Approved
GM6001The serum concentration of Rosuvastatin can be increased when it is combined with GM6001.Experimental
IdelalisibThe serum concentration of Rosuvastatin can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Rosuvastatin can be increased when it is combined with idraparinux.Investigational
ImatinibThe metabolism of Rosuvastatin can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Rosuvastatin can be increased when it is combined with Imidapril.Investigational
IndinavirThe serum concentration of Rosuvastatin can be increased when it is combined with Indinavir.Approved
IrbesartanThe metabolism of Rosuvastatin can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Rosuvastatin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe serum concentration of Rosuvastatin can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe metabolism of Rosuvastatin can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Rosuvastatin can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Rosuvastatin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Rosuvastatin can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Rosuvastatin can be increased when it is combined with Ixazomib.Approved
KetoconazoleThe metabolism of Rosuvastatin can be decreased when combined with Ketoconazole.Approved, Investigational
Lanthanum carbonateThe serum concentration of Lanthanum carbonate can be decreased when it is combined with Rosuvastatin.Approved
LedipasvirThe serum concentration of Rosuvastatin can be increased when it is combined with Ledipasvir.Approved
LeflunomideThe metabolism of Rosuvastatin can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinThe serum concentration of Rosuvastatin can be increased when it is combined with Lepirudin.Approved
LinagliptinThe serum concentration of Rosuvastatin can be increased when it is combined with Linagliptin.Approved
LisinoprilThe serum concentration of Rosuvastatin can be increased when it is combined with Lisinopril.Approved, Investigational
LopinavirThe serum concentration of Rosuvastatin can be increased when it is combined with Lopinavir.Approved
LosartanThe metabolism of Rosuvastatin can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Rosuvastatin can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Rosuvastatin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Rosuvastatin can be decreased when it is combined with Lumacaftor.Approved
MagaldrateThe serum concentration of Rosuvastatin can be decreased when it is combined with Magaldrate.Withdrawn
Magnesium carbonateThe serum concentration of Rosuvastatin can be decreased when it is combined with Magnesium carbonate.Approved
Magnesium HydroxideThe serum concentration of Rosuvastatin can be decreased when it is combined with Magnesium hydroxide.Approved
Magnesium oxideThe serum concentration of Rosuvastatin can be decreased when it is combined with Magnesium oxide.Approved
Magnesium TrisilicateThe serum concentration of Rosuvastatin can be decreased when it is combined with Magnesium Trisilicate.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Rosuvastatin is combined with Mecamylamine.Approved
MifepristoneThe serum concentration of Rosuvastatin can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Rosuvastatin can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Rosuvastatin can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Rosuvastatin can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Rosuvastatin can be increased when it is combined with Moexipril.Approved
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Rosuvastatin can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NafamostatThe serum concentration of Rosuvastatin can be increased when it is combined with Nafamostat.Approved, Investigational
NafcillinThe serum concentration of Rosuvastatin can be decreased when it is combined with Nafcillin.Approved
NCX 4016The serum concentration of Rosuvastatin can be increased when it is combined with NCX 4016.Investigational
NefazodoneThe metabolism of Rosuvastatin can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Rosuvastatin can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Rosuvastatin can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Rosuvastatin can be increased when combined with Nevirapine.Approved
NiacinThe risk or severity of adverse effects can be increased when Niacin is combined with Rosuvastatin.Approved, Investigational, Nutraceutical
NicardipineThe metabolism of Rosuvastatin can be decreased when combined with Nicardipine.Approved
NicotinamideThe risk or severity of adverse effects can be increased when Nicotinamide is combined with Rosuvastatin.Approved
NilotinibThe metabolism of Rosuvastatin can be decreased when combined with Nilotinib.Approved, Investigational
NitroaspirinThe serum concentration of Rosuvastatin can be increased when it is combined with Nitroaspirin.Investigational
OlaparibThe metabolism of Rosuvastatin can be decreased when combined with Olaparib.Approved
OmapatrilatThe serum concentration of Rosuvastatin can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Rosuvastatin can be increased when it is combined with Ombitasvir.Approved
OmeprazoleThe metabolism of Rosuvastatin can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Rosuvastatin can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Rosuvastatin can be increased when it is combined with Otamixaban.Investigational
PalbociclibThe serum concentration of Rosuvastatin can be increased when it is combined with Palbociclib.Approved
PantoprazoleThe metabolism of Rosuvastatin can be decreased when combined with Pantoprazole.Approved
ParitaprevirThe serum concentration of Rosuvastatin can be increased when it is combined with Paritaprevir.Approved
PazopanibRosuvastatin may increase the hepatotoxic activities of Pazopanib.Approved
PentobarbitalThe metabolism of Rosuvastatin can be increased when combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Rosuvastatin can be increased when it is combined with Perindopril.Approved
PhenindioneRosuvastatin may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Rosuvastatin can be increased when combined with Phenobarbital.Approved
PhenprocoumonRosuvastatin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe serum concentration of Rosuvastatin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Rosuvastatin can be increased when it is combined with Phosphoramidon.Experimental
PosaconazoleThe metabolism of Rosuvastatin can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe metabolism of Rosuvastatin can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Rosuvastatin can be increased when it is combined with Prinomastat.Investigational
PyrimethamineThe metabolism of Rosuvastatin can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe serum concentration of Rosuvastatin can be increased when it is combined with Quinapril.Approved, Investigational
QuinineThe serum concentration of Rosuvastatin can be increased when it is combined with Quinine.Approved
RacecadotrilThe serum concentration of Rosuvastatin can be increased when it is combined with Racecadotril.Investigational
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Rosuvastatin.Approved
RamiprilThe serum concentration of Rosuvastatin can be increased when it is combined with Ramipril.Approved
RanolazineThe metabolism of Rosuvastatin can be decreased when combined with Ranolazine.Approved, Investigational
RemikirenThe serum concentration of Rosuvastatin can be increased when it is combined with Remikiren.Approved
RifabutinThe metabolism of Rosuvastatin can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Rosuvastatin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Rosuvastatin can be increased when combined with Rifapentine.Approved
RitonavirThe serum concentration of Rosuvastatin can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rosuvastatin can be increased when it is combined with Rivaroxaban.Approved
RolapitantThe serum concentration of Rosuvastatin can be increased when it is combined with Rolapitant.Approved
SaquinavirThe serum concentration of Rosuvastatin can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Rosuvastatin can be increased when it is combined with Saxagliptin.Approved
SecobarbitalThe metabolism of Rosuvastatin can be increased when combined with Secobarbital.Approved, Vet Approved
SertralineThe metabolism of Rosuvastatin can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Rosuvastatin can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Rosuvastatin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Rosuvastatin can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Rosuvastatin can be increased when it is combined with Sitagliptin.Approved, Investigational
SorafenibThe metabolism of Rosuvastatin can be decreased when combined with Sorafenib.Approved, Investigational
SpiraprilThe serum concentration of Rosuvastatin can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Rosuvastatin can be increased when combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Rosuvastatin can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Rosuvastatin can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Rosuvastatin can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Rosuvastatin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TelaprevirThe serum concentration of Rosuvastatin can be increased when it is combined with Telaprevir.Approved
TelithromycinThe metabolism of Rosuvastatin can be decreased when combined with Telithromycin.Approved
TemocaprilThe serum concentration of Rosuvastatin can be increased when it is combined with Temocapril.Experimental, Investigational
TeriflunomideThe serum concentration of Rosuvastatin can be increased when it is combined with Teriflunomide.Approved
ThiorphanThe serum concentration of Rosuvastatin can be increased when it is combined with Thiorphan.Experimental
TicagrelorThe metabolism of Rosuvastatin can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Rosuvastatin can be decreased when combined with Ticlopidine.Approved
TipranavirThe serum concentration of Rosuvastatin can be increased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Rosuvastatin can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Rosuvastatin can be decreased when combined with Tolbutamide.Approved
TopiramateThe metabolism of Rosuvastatin can be decreased when combined with Topiramate.Approved
TrabectedinRosuvastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.Approved, Investigational
TrandolaprilThe serum concentration of Rosuvastatin can be increased when it is combined with Trandolapril.Approved
TranylcypromineThe metabolism of Rosuvastatin can be decreased when combined with Tranylcypromine.Approved
TrimethoprimThe metabolism of Rosuvastatin can be decreased when combined with Trimethoprim.Approved, Vet Approved
UbenimexThe serum concentration of Rosuvastatin can be increased when it is combined with Ubenimex.Experimental
UlinastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe metabolism of Rosuvastatin can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Rosuvastatin can be decreased when combined with Valsartan.Approved, Investigational
VenlafaxineThe metabolism of Rosuvastatin can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Rosuvastatin can be decreased when combined with Verapamil.Approved
VildagliptinThe serum concentration of Rosuvastatin can be increased when it is combined with Vildagliptin.Approved, Investigational
VoriconazoleThe metabolism of Rosuvastatin can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinRosuvastatin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Rosuvastatin can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
YM150The serum concentration of Rosuvastatin can be increased when it is combined with Ym150.Investigational
ZafirlukastThe metabolism of Rosuvastatin can be decreased when combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe metabolism of Rosuvastatin can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Valerie Niddam-Hildesheim, Greta Sterimbaum, “Process for preparation of rosuvastatin calcium.” U.S. Patent US20050080134, issued April 14, 2005.

US20050080134
General References
  1. Di Napoli P, Taccardi AA, Grilli A, De Lutiis MA, Barsotti A, Felaco M, De Caterina R: Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res. 2005 Jun 1;66(3):462-71. Epub 2005 Mar 2. [PubMed:15914111 ]
  2. Everett BM, Glynn RJ, MacFadyen JG, Ridker PM: Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation. 2010 Jan 5;121(1):143-50. doi: 10.1161/CIRCULATIONAHA.109.874834. Epub 2009 Dec 21. [PubMed:20026779 ]
  3. Jones SP, Gibson MF, Rimmer DM 3rd, Gibson TM, Sharp BR, Lefer DJ: Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol. 2002 Sep 18;40(6):1172-8. [PubMed:12354446 ]
  4. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003 Jul 15;92(2):152-60. [PubMed:12860216 ]
  5. Kilic E, Kilic U, Matter CM, Luscher TF, Bassetti CL, Hermann DM: Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase. Stroke. 2005 Feb;36(2):332-6. Epub 2004 Dec 29. [PubMed:15625301 ]
  6. Kosmidou I, Moore JP, Weber M, Searles CD: Statin treatment and 3' polyadenylation of eNOS mRNA. Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2642-9. Epub 2007 Oct 4. [PubMed:17916773 ]
  7. Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M: Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res. 2002 Jun 28;942(1-2):23-30. [PubMed:12031849 ]
  8. McKillop T: The statin wars. Lancet. 2003 Nov 1;362(9394):1498. [PubMed:14602449 ]
  9. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M: Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001 Mar 8;87(5A):28B-32B. [PubMed:11256847 ]
  10. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006 Apr 5;295(13):1556-65. Epub 2006 Mar 13. [PubMed:16533939 ]
  11. Stalker TJ, Lefer AM, Scalia R: A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol. 2001 Jun;133(3):406-12. [PubMed:11375257 ]
  12. Authors unspecified: The statin wars: why AstraZeneca must retreat. Lancet. 2003 Oct 25;362(9393):1341. [PubMed:14585629 ]
  13. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB: Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806. Epub 2006 Mar 6. [PubMed:16697742 ]
External Links
ATC CodesC10BX10C10BX05C10AA07C10BA06C10BX07C10BX09
AHFS Codes
  • 24:06.08
PDB EntriesNot Available
FDA labelDownload (270 KB)
MSDSDownload (57.8 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceAtherosclerosis / Inflammatory Activity in Carotid Arteries1
0CompletedBasic ScienceAtherosclerosis / Inflammatory Activity in Coronary Arteries1
0CompletedTreatmentHIV Seropositivity1
0RecruitingTreatmentFriedreich's Ataxia1
0Unknown StatusPreventionPatients With Coronary Artery Disease Scheduled for by Pass Surgery1
1Active Not RecruitingNot AvailableHealthy Volunteers1
1Active Not RecruitingOtherHigh Risk Coronary Artery Disease1
1Active Not RecruitingTreatmentHealthy Volunteers1
1Active Not RecruitingTreatmentNeoplasms1
1Active Not RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)1
1CompletedNot AvailableAcute Coronary Syndromes (ACS)1
1CompletedNot AvailableDiabetes Mellitus, Type 21
1CompletedNot AvailableDrug Interactions / Healthy Volunteers / Pharmacokinetics1
1CompletedNot AvailableHIV/AIDS1
1CompletedNot AvailableHealthy Volunteers5
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of ASP015K1
1CompletedNot AvailableHepatitis C1
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
1CompletedNot AvailableHypercholesterolaemia1
1CompletedNot AvailableHypertensive3
1CompletedNot AvailableImmunosuppression For Disease1
1CompletedBasic ScienceCYP2C19 Poor / Extensive Metabolizers1
1CompletedBasic ScienceDrug Interaction Potentiation1
1CompletedBasic ScienceDrug Interactions1
1CompletedBasic ScienceDrug-Drug Interaction (DDI) / Healthy Volunteers / Intestinal Absorption / Pharmacokinetics of Fidaxomicin / Pharmacokinetics of Rosuvastatin1
1CompletedBasic ScienceHealthy Volunteers3
1CompletedBasic SciencePharmacokinetic Variables1
1CompletedBasic ScienceRheumatoid Arthritis1
1CompletedOtherHypertensive1
1CompletedScreeningDyslipidemias1
1CompletedSupportive CareHealthy Male Volunteers1
1CompletedTreatmentAcute Coronary Syndromes (ACS) / Angioplasty, Transluminal, Percutaneous Coronary / Blood Platelets / Hydroxymethylglutaryl-CoA Reductase Inhibitors1
1CompletedTreatmentAdverse Events / Pharmacokinetic Variables1
1CompletedTreatmentAdverse Events / Pharmacokinetics1
1CompletedTreatmentAnemias1
1CompletedTreatmentAsthma1
1CompletedTreatmentAtherosclerosis1
1CompletedTreatmentAtherosclerosis / Hypercholesterolaemia1
1CompletedTreatmentDiabetes Mellitus (DM)3
1CompletedTreatmentDiabetes / Hyperlipidemias1
1CompletedTreatmentDyslipidemia, Renal Insufficiency1
1CompletedTreatmentHealthy Volunteers20
1CompletedTreatmentHepatitis C Virus (HCV)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHyperlipidemias / Hypertensive6
1CompletedTreatmentHypertension and Dyslipidemia1
1CompletedTreatmentHypertensive1
1CompletedTreatmentHypertriglyceridemias1
1CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC) / Squamous Cell Carcinoma (SCC)1
1CompletedTreatmentSkin Diseases, Bacterial1
1CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
1Enrolling by InvitationNot AvailableHealthy Volunteers1
1Enrolling by InvitationTreatmentHealthy Volunteers1
1Not Yet RecruitingBasic ScienceHealthy Volunteers1
1Not Yet RecruitingTreatmentHealthy Volunteers1
1RecruitingBasic ScienceAutoimmune Diseases / Inflammatory Diseases1
1RecruitingBasic ScienceHealthy Volunteers1
1RecruitingBasic ScienceStatin Pharmacokinetics Pre and Post Gastric Bypass Surgery1
1RecruitingTreatmentCancer, Breast1
1RecruitingTreatmentDiabetes / Healthy Volunteers1
1RecruitingTreatmentDiabetes / Hyperlipidemias1
1RecruitingTreatmentDyslipidemias1
1RecruitingTreatmentHyperlipidemias / Hypertensive1
1RecruitingTreatmentProstatic Neoplasms, Castration-Resistant1
1RecruitingTreatmentCMET-dysregulated Advanced Solid Tumors1
1TerminatedTreatmentCardiovascular Complications / Recurrent Breast Cancer / Stage I Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1TerminatedTreatmentHyperlipidemias / Hypertensive1
1TerminatedTreatmentMalaria1
1Unknown StatusTreatmentHealthy Volunteers1
1, 2CompletedTreatmentHead Injuries1
1, 2Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1, 2Unknown StatusTreatmentSevere Pre-eclampsia1
2Active Not RecruitingPreventionDeep Vein Thrombosis (DVT) / Neoplasms / Venous Thromboembolism1
2Active Not RecruitingSupportive CareCancer, Breast1
2CompletedPreventionBurns1
2CompletedPreventionHeart Diseases / Human Immunodeficiency Virus (HIV) Infections1
2CompletedPreventionHypercholesterolaemia1
2CompletedTreatmentAtherosclerosis / Systemic Lupus Erythematosus (SLE)1
2CompletedTreatmentCardiovascular Diseases / Endothelial Dysfunction1
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2CompletedTreatmentCoronary Artery Disease / Obstructive Coronary Artery Disease1
2CompletedTreatmentDiabetes Mellitus (DM)1
2CompletedTreatmentDiabetic Polyneuropathy1
2CompletedTreatmentDiabetic Polyneuropathy / Oxidative Stress1
2CompletedTreatmentDyslipidemias2
2CompletedTreatmentHead Injuries1
2CompletedTreatmentHeart Failure (HF)1
2CompletedTreatmentHepatitis C1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Hyperlipidemias1
2CompletedTreatmentHyperlipidemias1
2CompletedTreatmentIntracerebral Hemorrhage / Stroke1
2CompletedTreatmentIschaemia1
2CompletedTreatmentPlatelet Dysfunction1
2CompletedTreatmentRheumatoid Arthritis1
2Not Yet RecruitingTreatmentCoronary Heart Disease (CHD) / Human Immunodeficiency Virus (HIV) Infections1
2Not Yet RecruitingTreatmentCoronary Syndrome1
2Not Yet RecruitingTreatmentDyslipidemias1
2RecruitingPreventionVenous Thromboembolism1
2RecruitingTreatmentArteriovenous Fistulas / Diabetes Mellitus (DM) / End-Stage Kidney Disease1
2RecruitingTreatmentRectal Cancers1
2RecruitingTreatmentVenous Thromboembolism / Wounds and Injuries1
2TerminatedBasic ScienceCoronary Artery Disease / Dyslipidemias1
2TerminatedTreatmentCritically Ill / H1N1/Influenza Infection1
2TerminatedTreatmentInfluenza A Virus Infection1
2Unknown StatusNot AvailableHIV-1 Infections1
2Unknown StatusTreatmentAcute Myocardial Infarction (AMI)1
2Unknown StatusTreatmentDepression1
2Unknown StatusTreatmentSepsis 1
2, 3CompletedTreatmentChronic Periodontitis2
2, 3CompletedTreatmentRheumatoid Arthritis1
2, 3RecruitingTreatmentHyperlipidemias1
2, 3TerminatedTreatmentCardiovascular Diseases / Human Immunodeficiency Virus (HIV) Infections1
3Active Not RecruitingTreatmentAtherosclerosis1
3Active Not RecruitingTreatmentHypercholesterolaemia / Hypercholesterolemia, Familial1
3CompletedNot AvailableHypercholesteremia1
3CompletedPreventionHeart Failure (HF)1
3CompletedPreventionRenal Failure1
3CompletedTreatmentAcute Coronary Syndromes (ACS)2
3CompletedTreatmentAortic Stenosis1
3CompletedTreatmentAssess the Periprocedural Myocardial Necrosis1
3CompletedTreatmentAtherosclerosis2
3CompletedTreatmentAtherosclerosis / Cardiovascular Diseases1
3CompletedTreatmentAtherosclerosis / Coronary Heart Disease (CHD) / Hypercholesterolaemia2
3CompletedTreatmentCardiovascular Disorder / Diabetes Mellitus (DM)1
3CompletedTreatmentCarotid Artery Stenosis / Hypercholesterolaemia1
3CompletedTreatmentCholesterolemia / Hypertensive1
3CompletedTreatmentCongestive Cardiomyopathy1
3CompletedTreatmentCongestive Heart Failure (CHF)1
3CompletedTreatmentCoronary Arteriosclerosis1
3CompletedTreatmentCoronary Artery Disease / Myocardial Ischemia1
3CompletedTreatmentCoronary Atherosclerosis1
3CompletedTreatmentCoronary Heart Disease (CHD) / Dyslipidemias / Mixed hypercholesterolemia2
3CompletedTreatmentCoronary Heart Disease (CHD) / Hypercholesterolaemia1
3CompletedTreatmentDiabetic Dyslipidemia / Type 2 Diabetes Mellitus (T2DM)1
3CompletedTreatmentDyslipidemias1
3CompletedTreatmentDyslipidemias / Hypercholesterolaemia4
3CompletedTreatmentDyslipidemias / Hypertensive1
3CompletedTreatmentDyslipidemias / Kidney Diseases1
3CompletedTreatmentDyslipidemias / Metabolic Syndromes2
3CompletedTreatmentEssential Hypertension, Dyslipidemia1
3CompletedTreatmentFredrickson Type IIa & Type IIb Dyslipidaemia1
3CompletedTreatmentHeart Failure (HF)1
3CompletedTreatmentHeart Failure (HF) / Positron Emission Tomography (PET) / Rosuvastatin1
3CompletedTreatmentHomozygous Familial Hypercholesterolemia (HoFH)2
3CompletedTreatmentHypercholesteremia1
3CompletedTreatmentHypercholesterolaemia19
3CompletedTreatmentHypercholesterolemia, Familial3
3CompletedTreatmentHyperlipidemias1
3CompletedTreatmentHyperlipidemias / Hypertensive2
3CompletedTreatmentHyperlipoproteinemia Type III1
3CompletedTreatmentMetabolic Syndromes1
3CompletedTreatmentObesity, Abdominal1
3CompletedTreatmentPeriprocedural Myocardial Necrosis1
3CompletedTreatmentSystemic Sclerosis1
3CompletedTreatmentType 2 Diabetes Mellitus (T2DM)1
3CompletedTreatmentMixed hypercholesterolemia1
3Not Yet RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3RecruitingPreventionANCA-associated Primary Necrotizing Vasculitides1
3RecruitingPreventionAtherosclerotic Disease / Postoperative Bleeding1
3RecruitingPreventionCardiovascular Diseases / Coronary Artery Disease / Diabetes Mellitus, Type 21
3RecruitingTreatmentCoronary Artery Disease1
3RecruitingTreatmentDiabetes, Type II / Dyslipidemias1
3RecruitingTreatmentDyslipidemias / Type 2 Diabetes Mellitus (T2DM)1
3RecruitingTreatmentHypercholesterolaemia2
3RecruitingTreatmentHyperlipidemias / Hypertensive1
3TerminatedPreventionElevated High-sensitivity C-Reactive Protein (hsCRP)1
3TerminatedTreatmentAcute Lung Injury (ALI) / Sepsis 1
3TerminatedTreatmentColorectal Cancers / Precancerous Conditions1
3TerminatedTreatmentHip Fractures1
3TerminatedTreatmentHypercholesterolaemia3
3TerminatedTreatmentStable Coronary Artery Disease Undergoing PCI1
3TerminatedTreatmentStroke1
3Unknown StatusPreventionCoronary Heart Disease (CHD)1
3Unknown StatusTreatmentCoronary Artery Disease1
3Unknown StatusTreatmentHypercholesterolaemia1
3Unknown StatusTreatmentHyperlipidemias / Hypertensive1
3Unknown StatusTreatmentValvular Cardiac Surgery1
3Unknown StatusTreatmentMixed hypercholesterolemia1
3WithdrawnTreatmentProphylaxis of Pulmonary embolism / Thrombosis, Venous1
4Active Not RecruitingTreatment22q Telomere Deletion Syndrome / Telomere Length, Mean Leukocyte / Telomere Shortening1
4Active Not RecruitingTreatmentCoronary Arteriosclerosis1
4Active Not RecruitingTreatmentHyperlipidemias / Sexual Dysfunctions1
4Active Not RecruitingTreatmentStroke, Ischemic1
4CompletedNot AvailableAtherosclerosis / Hypercholesterolaemia1
4CompletedNot AvailableCoronary Heart Disease (CHD)1
4CompletedNot AvailableSexual Dysfunctions1
4CompletedHealth Services ResearchDiabetes Mellitus (DM) / Dyslipidemias1
4CompletedPreventionAcute Coronary Syndromes (ACS)2
4CompletedPreventionAdverse Effects / Coronary Atherosclerosis / Insulin resistance syndrome1
4CompletedPreventionAtherosclerosis / Cardiovascular Diseases1
4CompletedPreventionAtherosclerosis / Systemic Lupus Erythematosus (SLE) / Thromboembolism1
4CompletedPreventionCardiovascular Diseases / Stroke1
4CompletedPreventionChronic Kidney Disease (CKD) / Diabetes Mellitus (DM)1
4CompletedPreventionEndothelial Dysfunction / Ischemia Reperfusion Injury1
4CompletedPreventionIschemia Reperfusion Injury1
4CompletedPreventionMyocardium; Injury / Nonvalvular Atrial Fibrillation1
4CompletedPreventionNephropathies1
4CompletedSupportive CareA Total of 234 Patients With Acute Coronary Syndrome Who Will Undergo OPCAB1
4CompletedTreatmentAcute Coronary Syndromes (ACS) / Dyslipidemias1
4CompletedTreatmentAngina Pectoris1
4CompletedTreatmentAtherosclerosis / Coronary Heart Disease (CHD) / Diabetes / Dyslipidemias / Stroke1
4CompletedTreatmentAtherosclerosis / Endothelial Dysfunction1
4CompletedTreatmentCardiovascular Risk Factors / Hypertensive1
4CompletedTreatmentCoronary Artery Disease2
4CompletedTreatmentCoronary Artery Disease / Hyperlipidemias1
4CompletedTreatmentDiabetes2
4CompletedTreatmentDiabetes Mellitus, Type 2 / Hypertriglycemia1
4CompletedTreatmentDisorder Related to Renal Transplantation / Hypercholesterolaemia1
4CompletedTreatmentFurcation Defects1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Hyperlipidemias1
4CompletedTreatmentHypercholesteremia1
4CompletedTreatmentHypercholesterolaemia4
4CompletedTreatmentHypercholesterolemia, Familial1
4CompletedTreatmentHyperlipidemias1
4CompletedTreatmentHyperlipidemias / Hyperlipoproteinemia Type IIb / Hyperlipoproteinemia Type iv / Hyperlipoproteinemia Type V / Hypertriglyceridemias1
4CompletedTreatmentMetabolic Syndromes2
4CompletedTreatmentMyocardial Infarction [C14.907.585.500]1
4CompletedTreatmentOrganic Anion Transporting Polypeptide1B1 (OATP1B1) / Rosuvastatin1
4CompletedTreatmentST-Segment Elevation Myocardial Infarction / Subclinical Carotid Atherosclerosis1
4CompletedTreatmentType 2 Diabetes Mellitus (T2DM)1
4CompletedTreatmentType IIa and IIb Hypercholesterolaemia1
4Enrolling by InvitationTreatmentAtherosclerosis1
4Enrolling by InvitationTreatmentCerebral Infarctions / CLOPIDOGREL, POOR METABOLISM of (Disorder)1
4Enrolling by InvitationTreatmentComplete Occlusion of Coronary Artery / Hibernation, Myocardial1
4Not Yet RecruitingPreventionCoronary Artery Disease1
4Not Yet RecruitingTreatmentArterial Hypertension1
4Not Yet RecruitingTreatmentAtherosclerosis1
4Not Yet RecruitingTreatmentInfarction, Anterior Cerebral Artery1
4Not Yet RecruitingTreatmentIntracranial Arterial Stenosis1
4Not Yet RecruitingTreatmentIschemic1
4Not Yet RecruitingTreatmentParoxysmal Atrial Fibrillation (PAF)1
4RecruitingDiagnosticCardiovascular Disease (CVD) / Human Immunodeficiency Virus (HIV)1
4RecruitingHealth Services ResearchDiabetes1
4RecruitingPreventionHypertensive / Stroke / Transient Ischemic Attack (TIA)1
4RecruitingTreatmentAcute Coronary Syndromes (ACS)1
4RecruitingTreatmentAcute Coronary Syndromes (ACS) / Hypercholesterolaemia1
4RecruitingTreatmentCardiovascular Diseases1
4RecruitingTreatmentCardiovascular Diseases / Coronary Artery Disease / Coronary Disease1
4RecruitingTreatmentCarotid Atherosclerosis1
4RecruitingTreatmentHealthy Volunteers1
4RecruitingTreatmentHypercholesterolaemia1
4RecruitingTreatmentHypertensive1
4RecruitingTreatmentMetabolic Syndromes1
4RecruitingTreatmentMyocardial Fibrosis1
4RecruitingTreatmentST Elevation (STEMI) Myocardial Infarction1
4TerminatedNot AvailableDyslipidemias1
4TerminatedNot AvailableStatin Adverse Reaction / Statin-Associated Myopathy1
4TerminatedTreatmentAtherosclerosis / Coronary Artery Disease / Hypercholesterolaemia1
4TerminatedTreatmentAtherosclerosis / Human Immunodeficiency Virus (HIV) Infections1
4TerminatedTreatmentHypercholesterolaemia1
4TerminatedTreatmentStroke / Transient Ischemic Attack (TIA)1
4Unknown StatusPreventionCardiovascular Diseases / HIV Disease1
4Unknown StatusTreatmentAcute Coronary Syndromes (ACS)1
4Unknown StatusTreatmentAtherosclerosis / Hyperlipidemias1
4Unknown StatusTreatmentCoronary Artery Disease4
4Unknown StatusTreatmentCoronary Artery Disease / Hyperlipidemias1
4Unknown StatusTreatmentCoronary Artery Dissection, Spontaneous1
4Unknown StatusTreatmentCoronary Disease / Hypercholesterolaemia1
4Unknown StatusTreatmentDyslipidemias1
4Unknown StatusTreatmentFocus of Study1
4Unknown StatusTreatmentHigh LDL Cholesterol Level / Systemic Lupus Erythematosus (SLE)1
4Unknown StatusTreatmentHypercholesterolaemia1
4Unknown StatusTreatmentNon-ST-elevation Acute Coronary Syndromes1
4Unknown StatusTreatmentNonfamilial Hypercholesterolemia / Physical Inactivity1
4Unknown StatusTreatmentSleep Apnea, Obstructive1
4WithdrawnBasic ScienceDiabetes / Glaucoma1
4WithdrawnTreatmentHypercholesterolemia, Familial1
Not AvailableCompletedNot AvailableAnkylosing Spondylitis (AS) / Carotid Artery Plaque / Rheumatoid Arthritis1
Not AvailableCompletedNot AvailableCardiovascular Diseases / Diabetes Mellitus, Type 21
Not AvailableCompletedNot AvailableCerebrovascular Accidents / Coronary Heart Disease (CHD) / Diabetes / Hypercholesterolaemia / Peripheral Vascular Disease (PVD)1
Not AvailableCompletedNot AvailableHypercholesterolaemia2
Not AvailableCompletedBasic ScienceAdenosine Metabolism1
Not AvailableCompletedBasic ScienceDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism1
Not AvailableCompletedTreatmentAcute Coronary Syndromes (ACS)1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Hypercholesterolaemia1
Not AvailableCompletedTreatmentHypercholesterolemia With Concomitant Type 2 Diabetes1
Not AvailableNot Yet RecruitingTreatmentCardiovascular Diseases / Cerebrovascular Diseases / Peripheral Atherosclerotic Disease1
Not AvailableRecruitingPreventionAcute Coronary Syndromes (ACS)1
Not AvailableRecruitingTreatmentArteriosclerosis / Diabetes Mellitus (DM) / Lipid Disorders1
Not AvailableRecruitingTreatmentCoronary Artery Occlusive Disease1
Not AvailableRecruitingTreatmentIntracranial Arterial Diseases1
Not AvailableTerminatedPreventionHypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus (T2DM)1
Not AvailableTerminatedTreatmentAcute Respiratory Distress Syndrome (ARDS) / Flu caused by Influenza / Influenza A Virus Infection1
Not AvailableUnknown StatusTreatmentAcute Coronary Syndromes (ACS) / Diabetes Mellitus (DM)1
Not AvailableUnknown StatusTreatmentAcute Respiratory Distress Syndrome (ARDS) / Blunt Chest Trauma1
Not AvailableUnknown StatusTreatmentHypercholesterolaemia1
Not AvailableWithdrawnNot AvailablePCI Patients1
Not AvailableWithdrawnTreatmentHepatitis C1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tablet, coatedOral10 mg/1
Tablet, coatedOral40 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral5 mg/1
TabletOral10 mg
TabletOral20 mg
TabletOral40 mg
TabletOral5 mg
TabletOral10.0 mg
TabletOral20.0 mg
TabletOral40.0 mg
TabletOral5.0 mg
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral5 mg/1
Tablet, coatedOral20 mg/1
Tablet, coatedOral5 mg/1
Prices
Unit descriptionCostUnit
Crestor 40 mg tablet4.7USD tablet
Crestor 20 mg tablet4.69USD tablet
Crestor 10 mg tablet4.68USD tablet
Crestor 5 mg tablet4.68USD tablet
Crestor 40 mg Tablet2.24USD tablet
Crestor 20 mg Tablet1.91USD tablet
Crestor 10 mg Tablet1.53USD tablet
Crestor 5 mg Tablet1.45USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2072945 No2001-07-312012-07-02Canada
CA2315141 No2009-08-182020-08-04Canada
US6316460 Yes2001-02-042021-02-04Us
US6858618 Yes2002-06-172022-06-17Us
US7030152 Yes1998-10-022018-10-02Us
US7964614 Yes1998-10-022018-10-02Us
USRE37314 Yes1996-07-082016-07-08Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySparingly soluble in waterFDA label
logP0.13 FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.0886 mg/mLALOGPS
logP1.47ALOGPS
logP1.92ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)4ChemAxon
pKa (Strongest Basic)-2.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area140.92 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity121.44 m3·mol-1ChemAxon
Polarizability48.55 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9791
Blood Brain Barrier-0.6815
Caco-2 permeable-0.5818
P-glycoprotein substrateNon-substrate0.6962
P-glycoprotein inhibitor INon-inhibitor0.5099
P-glycoprotein inhibitor IINon-inhibitor0.8987
Renal organic cation transporterNon-inhibitor0.9467
CYP450 2C9 substrateNon-substrate0.5544
CYP450 2D6 substrateNon-substrate0.8633
CYP450 3A4 substrateNon-substrate0.584
CYP450 1A2 substrateNon-inhibitor0.6896
CYP450 2C9 inhibitorNon-inhibitor0.5957
CYP450 2D6 inhibitorNon-inhibitor0.8609
CYP450 2C19 inhibitorNon-inhibitor0.6414
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6226
Ames testNon AMES toxic0.662
CarcinogenicityNon-carcinogens0.6578
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5599 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9856
hERG inhibition (predictor II)Non-inhibitor0.8117
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpyrimidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrimidine ring through a CC or CN bond. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentPhenylpyrimidines
Alternative Parents
Substituents
  • 4-phenylpyrimidine
  • 5-phenylpyrimidine
  • Medium-chain hydroxy acid
  • Medium-chain fatty acid
  • Beta-hydroxy acid
  • Fluorobenzene
  • Halobenzene
  • Halogenated fatty acid
  • Heterocyclic fatty acid
  • Hydroxy fatty acid
  • Unsaturated fatty acid
  • Organosulfonic acid amide
  • Organic sulfonic acid amide
  • Fatty acyl
  • Fatty acid
  • Benzenoid
  • Aryl fluoride
  • Aryl halide
  • Monocyclic benzene moiety
  • Hydroxy acid
  • Aminosulfonyl compound
  • Heteroaromatic compound
  • Sulfonyl
  • Organosulfonic acid or derivatives
  • Organic sulfonic acid or derivatives
  • Secondary alcohol
  • Azacycle
  • Carboxylic acid derivative
  • Carboxylic acid
  • Monocarboxylic acid or derivatives
  • Organofluoride
  • Organonitrogen compound
  • Organooxygen compound
  • Hydrocarbon derivative
  • Organic oxide
  • Carbonyl group
  • Organosulfur compound
  • Organic oxygen compound
  • Organohalogen compound
  • Alcohol
  • Organic nitrogen compound
  • Organopnictogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Nadph binding
Specific Function:
Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including ubiquinone and geranylgeranyl proteins.
Gene Name:
HMGCR
Uniprot ID:
P04035
Molecular Weight:
97475.155 Da
References
  1. Carbonell T, Freire E: Binding thermodynamics of statins to HMG-CoA reductase. Biochemistry. 2005 Sep 6;44(35):11741-8. [PubMed:16128575 ]
  2. Chapman MJ, Caslake M, Packard C, McTaggart F: New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10. [PubMed:12539816 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  4. Davidson MH: Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs. 2002 Jan;11(1):125-41. [PubMed:11772327 ]
  5. Hanefeld M: Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor. Int J Clin Pract. 2001 Jul-Aug;55(6):399-405. [PubMed:11501230 ]
  6. Holdgate GA, Ward WH, McTaggart F: Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans. 2003 Jun;31(Pt 3):528-31. [PubMed:12773150 ]
  7. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M: Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001 Mar 8;87(5A):28B-32B. [PubMed:11256847 ]
  8. Olsson AG, McTaggart F, Raza A: Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2002 Winter;20(4):303-28. [PubMed:12481202 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Olsson AG, McTaggart F, Raza A: Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2002 Winter;20(4):303-28. [PubMed:12481202 ]
  2. Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81. [PubMed:17178259 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG: Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010 Feb 5;106(2):297-306. doi: 10.1161/CIRCRESAHA.109.203596. Epub 2009 Nov 25. [PubMed:19940267 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG: Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010 Feb 5;106(2):297-306. doi: 10.1161/CIRCRESAHA.109.203596. Epub 2009 Nov 25. [PubMed:19940267 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB: Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806. Epub 2006 Mar 6. [PubMed:16697742 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. van de Steeg E, Greupink R, Schreurs M, Nooijen IH, Verhoeckx KC, Hanemaaijer R, Ripken D, Monshouwer M, Vlaming ML, DeGroot J, Verwei M, Russel FG, Huisman MT, Wortelboer HM: Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1. Drug Metab Dispos. 2013 Mar;41(3):592-601. doi: 10.1124/dmd.112.049023. Epub 2012 Dec 17. [PubMed:23248200 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB: Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806. Epub 2006 Mar 6. [PubMed:16697742 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Molecular Weight:
76709.98 Da
References
  1. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB: Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806. Epub 2006 Mar 6. [PubMed:16697742 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Cystine:glutamate antiporter activity
Specific Function:
Sodium-independent, high-affinity exchange of anionic amino acids with high specificity for anionic form of cystine and glutamate.
Gene Name:
SLC7A11
Uniprot ID:
Q9UPY5
Molecular Weight:
55422.44 Da
References
  1. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB: Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806. Epub 2006 Mar 6. [PubMed:16697742 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Jemnitz K, Veres Z, Tugyi R, Vereczkey L: Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes. Toxicol In Vitro. 2010 Mar;24(2):605-10. doi: 10.1016/j.tiv.2009.10.009. Epub 2009 Oct 21. [PubMed:19853032 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on March 28, 2017 04:06